Objective: Obesity promotes the development and progression of coronary heart disease (CHD), in part, through its association with hyperlipidemia, hypertension, clotting abnormalities and insulin resistance. We assessed whether these relationships persist in patients with established CHD treated with evidence-based preventive pharmacologic therapies. Design and subjects: We performed a cross-sectional study of 74 adults with CHD and a body mass index (BMI) of 427 kg m -2 (mean 32±4). The mean age of subjects was 64±9 years (range 44-84 years). Measurements: Obesity measures included weight, BMI, waist, fat mass, intra-abdominal fat and subcutaneous fat. Risk factor measures included insulin sensitivity, fasting insulin level, lipid profiles, blood pressure, C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI-1) and platelet reactivity. Medication use included aspirin (99%), statin (84%), b-blocker (71%), ACE inhibitor or blocker (37%) and clopidogrel (28%). Results: There was no direct relationship between obesity parameters and risk factor measures of lipid concentrations, blood pressure, clotting abnormalities or platelet reactivity except for a modest relationship between visceral fat and hs-CRP (r ¼ 0.30, P ¼ 0.02). However, increased BMI, waist circumference, fat mass, total abdominal fat and abdominal subcutaneous fat all correlated with insulin sensitivity (r-values À0.30 to À0.45, P-values 0.01 to o0.001) and insulin concentrations. Insulin sensitivity, in turn, was the best predictor of PAI-1, triglycerides, high-density lipoprotein (HDL) levels, cholesterol/HDL levels (all Po0.01) and platelet reactivity (R ¼ 0.34, P ¼ 0.02). Conclusions: Use of preventive pharmacologic therapies obviated the expected relationship between adiposity and CHD risk factors. However, a residual effect of insulin resistance is left untreated. Total adiposity and central adiposity were strong predictors of insulin sensitivity, which in turn predicted cardiac risk factors such as lipid concentrations, PAI-1 and platelet reactivity. Thus, while evidence-based pharmacologic treatments may diminish the statistical relationship between obesity and many cardiac risk factors, adiposity negatively impacts CHD risk by reducing tissue insulin sensitivity.
Introduction
Obesity and insulin resistance are established risk factors for the development and progression of coronary heart disease (CHD). [1] [2] [3] [4] Increased adiposity is associated with an increased risk of death and recurrent cardiac events after myocardial infarction, despite treatment with established pharmacologic therapies. [5] [6] [7] The mechanism of this effect has not been fully elucidated, but it is presumed to act through obesity-related cardiac risk factors such as hyperinsulinemia, hyperlipidemia, hypertension, generalized inflammation and clotting abnormalities. 8, 9 However, no study has examined whether obesity remains a significant predictor of CHD risk factors in patients who are treated in accordance with evidence-based guidelines. Accordingly, the primary goal of our study was to examine whether the extent of total and central adiposity is associated with factors that confer an increased CHD risk in patients with established CHD. We, therefore, examined the relationship between total and central adiposity and CHD risk factors within a cohort of overweight patients with stable CHD who, following clinical review, were judged to be receiving optimal pharmacotherapy for cardiac risk reduction. We hypothesized that increasing levels of total and central obesity would continue to adversely affect CHD risk factors despite pharmacologic interventions (Figures 1 and 2 ). While recent studies of aggressive risk factor treatment in patients with stable CHD have documented a substantial reduction of future coronary events, significant risk persists. 10, 11 For example, in the PROVE-IT study of aggressive cholesterol lowering in patients with stable CHD, a 22% risk of death plus cardiovascular events was measured over a 2-year follow-up period in the intensively treated group of patients. 10 In the COURAGE trial, a 19% risk of death plus non-fatal myocardial infarction was measured over a median follow-up period of 4.6 years in patients with stable angina, despite optimal preventive medical therapy. Thus, our goal was to assess the relationship between obesity and predictors of cardiac risk in patients treated according to evidencebased guidelines. We also sought to identify indices of obesity that physicians can use in the clinical setting both to screen for obesity-related metabolic risk and to use as a target for therapy.
The presence of obesity is closely linked to insulin resistance and metabolic risk factors such as hyperlipidemia and hypertension, which characterize the metabolic syndrome. 8, [12] [13] [14] [15] The prevalence of a body mass index (BMI) X25 kg m -2 (overweight) or a BMI X30 kg m -2 (obesity) in patients with established CHD is over 80 and 40%, respectively. 16, 17 Furthermore, obesity and insulin resistance are associated with greater inflammatory tone, as reflected by elevated measures of C-reactive protein 9, 18 as well as abnormalities of coagulation, platelet function and fibrinolysis. 19 We have shown that the prevalence of metabolic syndrome in individuals with CHD is double that seen in the general population. 20 For these reasons, we determined insulin responsiveness using the euglycemic-hyperinsulinemic clamp technique as a criterion approach to measure modulators of other risk factors, such as hyperlipidemia, inflammation and coagulation abnormalities.
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Methods
The study population consisted of 74 individuals with stable CHD: 60 male and 14 female, none of whom had been hospitalized with an acute coronary event for 6 months.
Patients entered the study between 2002 and 2006. The presence of CHD was characterized by past myocardiac infarction (n ¼ 34), coronary bypass surgery (n ¼ 34), percutaneous coronary intervention (n ¼ 28) or chronic stable angina (n ¼ 6). Subjects with diabetes mellitus defined by a morning fasting glucose of X126 mg per 100 ml, or use of glucose-lowering medications, were excluded from the study. It is noted that 25 of the 74 patients had a fasting glucose of 100-126 mg per 100 ml. The mean age was 64±9 years (range 44-84 years, median 63 years) and all patients had a BMI of X27 kg m -2 (mean 32 ± 4, range 27-45). All the women were postmenopausal and none were taking hormone replacement therapy. Prior to testing, each patient underwent a clinical review with a preventive cardiologist (PA Ades), to ascertain that evidence-based clinical guidelines for pharmacologic therapies were being followed. It was recommended that all patients without a contraindication should be taking aspirin; all patients with an low-density lipoprotein cholesterol (LDL-Chol) of 4100 mg per 100 ml should initiate a statin or, if on a statin, should advance the dose; a beta-blocker was prescribed for all patients after myocardial infarction without an intervening revascularization, and subjects with a systolic blood pressure of 4140 mm Hg, diastolic blood pressure of 490 mm Hg or with a left ventricular ejection fraction of o40% were treated with an ACE inhibitor or an angiotensin receptor blocker.
Body composition was characterized by measurement of body weight, BMI, waist circumference, fat mass by dual X-ray absorptiometry, and intra-abdominal fat and subcutaneous thigh fat by computed tomography (CT) scanning. Open circles represent females and closed circles represent males.
Obesity and coronary risk factors in CHD PA Ades et al Dual X-ray absorptiometry scanning was analyzed using Lunar Radiation version 1.3z DPX-L. In our laboratory, the coefficient of variation for repeat dual X-ray absorptiometry determinations in seven healthy adults is 1% for fat mass and 1% for fat-free mass. Additionally, abdominal adipose tissue areas, mid-thigh muscle and subcutaneous fat areas were measured by CT (General Electric Medical Systems, Milwaukee, WI, USA; Philips Electronics N.V., Eindhoven, The Netherlands) as described previously. 21 Risk factor measures included insulin-stimulated glucose disposal, serum insulin levels, glucose levels, fasting lipid profiles, resting blood pressure, high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA) and ex vivo measures of platelet reactivity. Blood was drawn after a 12 h overnight fast, prior to taking morning medications. Exercise was restricted for 24 h prior to the blood draw.
Insulin-stimulated glucose disposal measurements were performed in the morning following a 12 h overnight fast using a 3 h euglycemic-hyperinsulinemic glucose clamp technique, as described previously. 21, 22 Testing was preceded ) was started to maintain levels at approximately postprandial levels. Euglycemia was maintained by adjusting a variable rate infusion of 20% dextrose. To minimize changes in plasma glucose enrichment during the clamp, [6,6-2 H 2 ]glucose (2 g; 98% 2 H) was added to the dextrose infusion. All infusions were stopped at 300 min except for the dextrose infusion, which was continued and tapered until no longer required to maintain normal glycemia. Blood samples were drawn prior to the start of infusion and at 270, 280, 290 and 300 for measurement of glucose kinetics under euglycemic hyperinsulinemia. Samples for insulin analysis were drawn just prior to the onset of insulin infusion. Plasma glucose concentrations were determined using a YSI glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH, USA). Plasma insulin levels were determined by radioimmunoassay (Linco, Los Angeles, CA, USA). Plasma endogenous hepatic glucose production was measured by electron impact ionization gas chromatography mass spectrometry, as previously described. 23, 24 Insulin-stimulated glucose uptake, an index of insulin sensitivity, was measured as the average dextrose infusion rate during the final 30 min of the euglycemic hyperinsulinemic clamp plus residual endogenous glucose production.
Residual endogenous glucose production was calculated as described previously. 21 Glucose disposal data were then expressed relative to fat-free mass. Total cholesterol (Chol) and triglyceride levels in plasma and lipoprotein fractions were determined by enzymatic methods. 25 The high-density lipoprotein cholesterol (HDLChol) fraction was measured in plasma supernatant after precipitation with dextran sulfate and magnesium sulfate. The formula of Friedewald 26 was used to calculate plasma LDL-Chol. Blood pressure (BP) was measured during an outpatient visit after 5 min in the seated position, using a Dynamap automated BP cuff, with a mean of three consecutive measurements taken as the resting BP. Mean BP was calculated by the equation
The concentrations of t-PA and PAI-1 were determined by enzyme-linked immunosorbent assay (Tintelize, Biopool, Umea, Sweden). We measured activity of PAI-1 with a spectrophotometric chromogenic procedure. 27 Plasma hs-CRP levels were measured using a colorimetric competitive enzyme-linked immunosorbent assay developed in-house. 28 The assay is based on the competition between biotinylated CRP and CRP in the sample for the coated antibody. To assay platelet function, blood was anticoagulated with corn trypsin inhibitor (Haematologic Technologies Inc. Essex, VT, USA), a direct inhibitor of Factor XIIa. Aliquots of 5 ml of whole blood were added to microcentrifuge tubes containing fluorochrome-labeled ligands and Hepes-Tyrode's buffer as previously described. 29, 30 Platelets were activated with selected concentrations (0, 0.2 and 1 mM) of adenosine diphosphate (ADP, BioData, Horsham, PA, USA) and 25 mM thrombin receptor agonist peptide (Bachem, Bubendorf, Switzerland). All assays were performed in duplicate. Flow cytometric analysis was performed with the use of a fluorescence-activated cell sorter (Beckman Coulter Epics Elite). Platelets were identified on the basis of size and binding of anti-CD61. Control samples were used to define a threshold above which activation-dependent binding occurred. Platelet activation was assessed as the percentage of platelets that bound fluorochrome-labeled fibrinogen or anti-CD62 that exceeded the percentage of the threshold defined with albumin and nonimmune IgG. Increased platelet reactivity has been shown to predict the occurrence of coronary events in patients after myocardial infarction, after a percutaneous coronary intervention and in apparently healthy men. 29, 31, 32 Cardiopulmonary fitness (peak aerobic capacity) was measured on the treadmill using a graded modified Balke protocol until volitional fatigue, the development of cardiovascular symptoms or the development of X2 mm ST segment depression on the electrocardiogram. 33 Expired gas was analyzed using a Sensormedics C 29 metabolic cart (Yorba Linda, CA, USA).
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Patients wore a Caltrac accelerometer (Country Technology, Inc.) for 7 days to estimate activity-related energy expenditure. The Caltrac estimates total activity-related energy expenditure through its measurement of the body's acceleration and deceleration. 34 Total activity-related energy expenditure includes both exercise-related energy expenditure and the calories used performing activities of daily living. The presence of mental depression was assessed using the Geriatric depression questionnaire. 35 Only 9 of 74 patients had mild symptoms of depression as signified by a score of X5 with a mean score of 2.1±2. 6 . We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. This protocol was approved by the Committee on Human Research at the University of Vermont College of Medicine.
Statistical analysis
Baseline results were compared between men and women using unpaired t-testing. Multiple regression analyses performed on the entire cohort were used to examine the relationship between obesity measures and insulin-stimulated glucose disposal as well as the relationships between these measures and cardiac risk predictors. The partial correlation coefficient (partial r) reported below measures the strength of the relationships after controlling for the effects of age and gender.
Results
All 74 study subjects were taking preventive cardiovascular medications in accordance with evidence-based guidelines as tolerated. 36 Medication use by study subjects is shown in Table 1 . There were no gender differences in prevalence of medication use. Body composition and body fat distribution parameters separated by gender are presented in Table 2 . The men were taller and heavier with a larger waist, a greater fat-free mass and mid-thigh muscle area (P-values range 0.005-o0.0001). There was a strong trend for more visceral fat in men vs women (P ¼ 0.06). The women had a greater percentage of body fat (Po0.0001), and higher levels of subcutaneous thigh fat (P ¼ 0.0005).
Risk factor measures are presented in Table 3 . Male patients demonstrated a lower insulin-stimulated glucose disposal during the hyperinsulinemic-euglycemic clamp (P ¼ 0.0004) reflecting a great level of insulin resistance with a trend (P ¼ 0.06) toward higher fasting insulin concentrations. The women had higher Chol than the men (P ¼ 0.002) and higher LDL-Chol (P ¼ 0.02) despite a similar rate of statin use (86% in women, 84% in men). Men had higher mean and diastolic BPs (P ¼ 0.005 and 0.02, respectively) whereas the women had higher concentrations of hs-CRP (P ¼ 0.039). There were no gender differences in concentrations of glucose, PAI-1 levels, t-PA or measures of platelet reactivity (results not shown). Men had both a higher absolute (l per min) and relative (ml per kg per min) measure of peak aerobic capacity vs women (P ¼ 0.007 and 0.0001, respectively).
We examined interactions between obesity parameters and coronary risk predictors with data adjusted by gender and age. Since obesity negatively influences coronary risk through its impact on insulin sensitivity and subsequent manifestation of the metabolic syndrome, 8, 14 we first evaluated the relationship between increasing extent of obesity and insulin-dependent glucose disposal as measured with the euglycemic-hyperinsulinemic glucose clamp expressed in milligrams glucose utilized per kg fat-free mass per min.
Measures of abdominal fat and overall adiposity were significantly related to glucose disposal. Waist circumference correlated with glucose disposal with a partial r-value of À0.36 (P ¼ 0.002). Total abdominal fat and abdominal subcutaneous fat measured by CT scan also correlated with glucose disposal (partial r-values À0.39 and À0.45, respectively, P-values 0.001 and o0.001, respectively). Generalized measures of obesity, such as BMI (partial r ¼ À0.36, P ¼ 0.002) and fat mass (partial r ¼ À0.30, P ¼ 0.012), also hada significant associations with glucose disposal. Both peak aerobic capacity, measured in l per min, and total daily physical activity measured by Caltrac were significantly associated with glucose disposal (partial r-values ¼ 0.25 and 0.29, respectively; P ¼ 0.043 and 0.015, respectively), however, these relationships were abolished when data were adjusted by indices of obesity. There was no relationship between age and glucose disposal measured in mg min -1 (P ¼ 0.21) or when adjusted by fat-free mass (mg per fat-free mass per min) (P ¼ 0.89). Fasting insulin level correlated with waist circumference (partial r ¼ 0.41, Po0.001), fat mass (partial r ¼ 0.41, Po0.001), total abdominal fat (partial r ¼ 0.36, P ¼ 0.004), BMI (partial r ¼ 0.34, P ¼ 0.005) and subcutaneous fat (partial r ¼ 0.33, P ¼ 0.007), but not with visceral fat (P ¼ 0.079) or peak aerobic capacity (P ¼ 0.736). The partial correlation coefficient between the fasting insulin concentration and glucose disposal was À0.27 (P ¼ 0.031). Fasting glucose measures were not associated with any of the measures of adiposity or fitness.
We then studied the relationships between measures of adiposity and other cardiac risk factors including lipid values (Chol, HDL-Chol, LDL-Chol, triglyceride and Chol/HDL ratio), hs-CRP, PAI-1 and platelet measures. None of the adiposity parameters were directly associated with lipid subfractions, although we note that use of cholesterollowering medications was high (84%). We note that glucose disposal correlated with HDL-Chol (partial r ¼ 0.40, P ¼ 0.001), log-triglycerides (partial r ¼ 0.40, P ¼ 0.001) and with the Chol/HDL ratio (partial r ¼ 0.36, P ¼ 0.003). Similarly, none of the measures of adiposity or body fat distribution were directly related to PAI-1 or t-PA concentrations, although glucose disposal correlated with PAI-1 (partial r ¼ À0.48, Po0.001) and t-PA (partial r ¼ À0.29, P ¼ 0.020). Intra-abdominal visceral fat area by CT scanning correlated with hs-CRP (partial r ¼ 0.30, P ¼ 0.024), although measures of glucose disposal and measures of adiposity or fat distribution did not correlate with hs-CRP. None of the measures of adiposity correlated with BP although, as with cholesterol measures, use of BP-lowering medications was high. Peak aerobic capacity showed a weak inverse correlation with diastolic BP (partial r ¼ 0.30, P ¼ 0.011). There was no relationship between depression score and BMI or glucose disposal.
Finally, we measured the relationship of adiposity indices and insulin sensitivity to ex vivo measures of platelet reactivity. In the total population, which included 21 patients taking clopidogrel, there were no significant relationships between adiposity or insulin sensitivity and platelet reactivity tested with agonists 0.2 mM ADP, 1.0 mM ADP and 25 mM thrombin receptor agonist peptide. Because clopidogrel attenuates activation induced by ADP and thrombin receptor agonist peptide, we reanalyzed these relationships in the 54 patients not taking clopidogrel and Abbreviations: BP, blood pressure; HDL-Chol., high-density cholesterol; hS-CRP, high-sensitivity C-reactive protein; LDL-Chol., low-density cholesterol; PAI-1, plasminogen activator inhibitor-1; Total Chol., total cholesterol; tPA, tissue plasminogen activator.
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Discussion
Because obesity per se is difficult to treat, physicians tend to treat the sequelae of obesity with pharmacologic agents rather than obesity itself. In the present study, we sought to determine whether the extent of adiposity, within an overweight cohort of patients with stable CHD and no evidence of diabetes, continues to predict coronary risk in the presence of comprehensive evidence-based pharmaceutical treatment of coronary risk factors. Contrary to our original hypothesis, we found that in the presence of lipid-lowering therapy, BP treatment and antiplatelet therapy, increasing extent of obesity was not significantly related to these CHD risk factors. One could conclude from our results that if one goal of evidence-based pharmacologic therapies is to reduce the risk factor correlates of obesity, 15, 37 the absence of relationships between obesity indices and risk factors suggests that these therapies are effective. The absence of relationships between adiposity indices and risk factors in the present study is in contrast to other studies that have repeatedly demonstrated such relationships in healthy individuals. 15, 37 We urge caution, however, in concluding that obesity no longer impacts risk factors in these patients. In our nondiabetic cohort, increasing levels of abdominal and whole-body obesity were strong predictors of insulin resistance and fasting insulin concentrations. Hyperinsulinemia is one of the hallmarks of the metabolic syndrome and is associated with an adverse CHD risk factor profile. 4, 8, 14 Our results indicate that insulin resistance was the strongest predictor of lipid abnormalities and prothrombotic measures. After myocardial infarction, lipid abnormalities, PAI-1 levels and measures of platelet reactivity are powerful predictors of long-term prognosis. 29, 31, 38, 39 Thus, our data suggest that obesity-related insulin resistance remains an important predictor of cardiovascular risk profile in overweight and obese patients with CHD and this finding was independent of age and gender. These findings identify tissue insulin sensitivity as a target for therapy in patients with chronic CHD who are treated according to current guidelines, but who nonetheless present a substantial risk for future coronary events. 10, 11 Our results imply a potential role for insulin-sensitizing agents, such as the thiazolidinediones, to improve the risk factor profile of overweight insulin-resistant individuals. However, until the effect of rosiglitazone and related agents on the risk of myocardial infarction and cardiac death is clarified in prospective trials, recent results preclude such a general approach. 40 These cross-sectional data suggest that an increase in insulin sensitivity would improve coronary risk in overweight patients with CHD. In overweight individuals without CHD, caloric restriction and exercise-induced weight loss improves many aspects of the insulin resistance syndrome. 41, 42 Lifestyle interventions that improve insulin sensitivity, therefore, may prove useful in further reducing risk factors in patients with established CHD beyond the benefits afforded by current pharmacotherapies. One hurdle during such interventions is gauging the effectiveness of the intervention to improve insulin sensitivity, since there is currently no way to measure it easily in a clinical setting. We observed, however, that several easily obtained clinical measures of adiposity, such as waist circumference and BMI, may serve as proxy indicators of insulin sensitivity, as they were both negatively related to insulin-stimulated glucose disposal. These measures, unlike measures obtained from radiologic imaging techniques, which are not widely available and expose the individual to ionizing radiation, can be easily monitored in the clinical setting. While desirable levels of waist circumference and BMI have been established for non-CHD populations 43 to reduce CHD risk, there are currently no data from which to generate guidelines for CHD patients taking evidence-based preventive medications to minimize CHD risk.
Limitations of the present study include that this was a cross-sectional analysis and we did not have longitudinal data available to assess the impact of obesity on long-term prognosis. Nonetheless, since patients with CHD, well treated by contemporary standards, have substantial longterm rates of clinical events, 10, 11 we can reasonably conjecture that the effects of adiposity comprise a component of that risk as demonstrated by others. [5] [6] [7] Another limitation is that our patient population entirely comprised overweight and obese individuals (BMI427 kg m -2 ). Thus, these data do not apply to lesser degrees of overweight or normal weight individuals, though others have shown that increasing abdominal obesity predicts insulin resistance even in normal weight individuals. 44 We specifically included overweight and obese individuals because the prevalence of being overweight (BMI 425 kg m -1 ) in patients with established CHD is 80% and the prevalence of obesity (BMI430 kg m -1 ) is 40%, 19, 20 which is considerably greater than the general American adult population (64 and 30%, respectively). 45 Third limitation is that the data were only taken with subjects taking their usual preventive medications. Had we additionally taken measures with patients after discontinuation of preventive medications, we could have provided insight into the effects of these medications on obesityrelated indices of cardiac risk. Finally, while these data suggest that weight loss would decrease coronary risk in optimally treated overweight individuals with CHD, an appropriately controlled prospective clinical intervention trial that incorporated an effective weight reduction program is needed to confirm this. In summary, although use of lipid-lowering agents, b-adrenergic blockers, ACE-inhibitors and antiplatelet agents in overweight and obese patients with established CHD diminishes the relationship of total and central obesity to those risk factors, adiposity continues to negatively impact CHD risk profile through its ability to impair tissue insulin sensitivity. In light of the limited pharmacotherapeutic options for improving insulin sensitivity, these results make a strong case for cardiac rehabilitation/secondary prevention centers to develop exercise and behavioral weight reduction programs specifically aimed at decreasing obesity and insulin resistance in this high-risk population.
